tert-butyl 5-formyl-2-thiophenecarboxylate | 135149-43-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: tert-butyl 5-formyl-2-thiophenecarboxylate
• 英文别名: 5-formyl-thiophene-2-carboxylic acid tert-butyl ester；5-formyl-2-thiophencarboxylic acid tert-butyl ester；tert-butyl 5-formylthiophene-2-carboxylate；t-butyl 5-formyl-2-thiophenecarboxylate
• CAS: 135149-43-8
• 化学式: C₁₀H₁₂O₃S
• 分子量: 212.269
• InChiKey: AXGWEMGJOUIUMX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  71.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 5-formyl-2-thiophenecarboxylate 在 水 、 羟胺 、 碳酸氢钠 、 溶剂黄146 、 三氟乙酸 、 锌 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 9.0h， 生成 5-((((9H-fluoren-9-yl)methoxy)carbonylamino)methyl)thiophene-2-carboxylic acid
  参考文献：
  名称：

  Identification of Potent and Selective Small-Molecule Inhibitors of Caspase-3 through the Use of Extended Tethering and Structure-Based Drug Design

  摘要：

  The design, synthesis, and in vitro activities of a series of potent and selective small-molecule inhibitors of caspase-3 are described. From extended tethering, a salicylic acid fragment was identified as having binding affinity for the S-4 pocket of caspase-3. X-ray crystallography and molecular modeling of the initial tethering hit resulted in the synthesis of 4, which reversibly inhibited caspase-3 with a K-i = 40 nM. Further optimization led to the identification of a series of potent and selective inhibitors with K-i values in the 20-50 nM range. One of the most potent compounds in this series, 66b, inhibited caspase-3 with a K-i = 20 nM and selectivity of 8-500-fold for caspase-3 vs a panel of seven caspases (1, 2, and 4-8). A high-resolution X-ray cocrystal structure of 4 and 66b supports the predicted binding modes of our compounds with caspase-3.

  DOI：

  10.1021/jm020230j
• 作为产物：
  描述：

  1,3-二甲基-2-(2-噻吩)咪唑烷 在 正丁基锂 、 四甲基乙二胺 、 碘甲烷 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 36.0h， 生成 tert-butyl 5-formyl-2-thiophenecarboxylate
  参考文献：
  名称：

  αvβ3 Antagonists Based on a Central Thiophene Scaffold

  摘要：

  A series of novel, highly potent alpha (v)beta (3) antagonists based on a thiophene scaffold and containing an acylguanidine as an Arg-mimetic is described. A number of structural features, such as cyclic versus open guanidine and a variety of lipophilic side chains, carbamates, sulfonamides and beta -amino acids were explored with respect to inhibition of alpha (v)beta (3) mediated cell adhesion and selectivity versus alpha (IIb)beta (3) binding. In addition, compound 19 was found to be active in the TPTX model of osteoporosis. (C) 2001 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(01)00357-2

文献信息

• Novel 6-5 Fused Ring Heterocycle Antifolates with Potent Antitumor Activity: Bridge Modifications and Heterocyclic Benzoyl Isosters of 2,4-Diamino-6,7-dihydro-5H-cyclopenta(d)pyrimidine Antifolate.
  作者：Yoshihiko KOTAKE、Tatsuo OKAUCHI、Atsumi IIJIMA、Kentaro YOSHIMATSU、Hiroaki NOMURA

  DOI：10.1248/cpb.43.829

  日期：——

  tumor cell growth, N-[4-[3-(2,4-diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidin-5- yl)propyl]benzoyl]-L-glutamic acid (1), have led to the synthesis of new cyclopenta[d]pyrimidine-based antifolates, including those with low alkyl substituted trimethylene bridges (2a, b) and isosterically modified bridges (ethyleneoxa, 2c; ethyleneamino, 2d; the N-methyl- and N-ethyl derivatives of 2d, 2e, f) and those

  结构强大的二氢叶酸还原酶（DHFR）活性和肿瘤细胞生长抑制剂N- [4- [3-（2,4-diamino-6,7-dihydro-5H-cyclopenta [d] pyrimidin-5-] （1）导致了新的基于环戊达[d]嘧啶的抗叶酸的合成，包括具有低烷基取代的亚丙基桥键（2a，b）和等位修饰桥键的化合物（亚乙基氧； 2c；亚乙基氨基2d； 2d，2e，f）的N-甲基和N-乙基衍生物以及其中1的苯环已被杂环等排物取代的化合物（吲哚，2g；二氢吲哚，2h；噻吩， 2i）。这些新的类似物作为DHFR和细胞生长抑制剂非常有效，在暴露于72小时的药物后，它们比甲氨蝶呤（MTX）和10-乙基-10-去氮杂蝶呤（10-EDAM）更有效地抑制肿瘤细胞的生长（对P388 MTX敏感和对MTX耐药，结肠26和KB） 。其中2a（1的10-甲基衍生物）和2i最有效，其效力比10-EDAM高2至3倍。药物暴
• NAMPT inhibitors
  申请人：AbbVie Inc.

  公开号：US09187472B2

  公开（公告）日：2015-11-17

  Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.

  揭示了抑制NAMPT活性的化合物，含有这些化合物的组合物以及治疗NAMPT表达期间的疾病的方法。
• SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF
  申请人：Blackburn Christopher

  公开号：US20110213003A1

  公开（公告）日：2011-09-01

  This invention provides compounds of formula (I): wherein X 1 , X 2 , X 3 , R 2 , R 4b , R 1 , and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  这项发明提供了式（I）的化合物： 其中X 1 ，X 2 ，X 3 ，R 2 ，R 4b ，R 1 和G的取值如规范中所述，可用作HDAC6的抑制剂。该发明还提供了包括该发明化合物的药物组合物，以及在治疗增殖性、炎症性、感染性、神经系统或心血管疾病或紊乱中使用这些组合物的方法。
• Pyrrolopyrimidines, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05354754A1

  公开（公告）日：1994-10-11

  A compound of the formula (I): ##STR1## wherein the ring A is a pyrrole ring which may be hydrogenated, X is an amino group, a hydroxyl group or a mercapto group, Y is a hydrogen atom or a hydroxyl group, --COOR.sup.1 and --COOR.sup.2 may be the same or different and are a carboxyl group which may be esterified, --B-- is a divalent heterocyclic group or a lower alkylene group each of which may be substituted, and Z is a straight C.sub.2-4 divalent group which may be substituted, or its salt, a method for the production of the same and an antitumor agent containing the same.

  该化合物的化学式（I）为：##STR1## 其中环A是一个吡咯环，可以是氢化的，X是氨基、羟基或巯基，Y是氢原子或羟基，--COOR.sup.1和--COOR.sup.2可以相同也可以不同，是可能酯化的羧基，--B--是二价杂环基团或低碳烷基基团，每个基团都可以被取代，Z是直链C.sub.2-4二价基团，可以被取代，或其盐，以及包含该化合物的生产方法和抗肿瘤剂。
• [EN] HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE<br/>[FR] DÉRIVÉ D'ESTER D'ACIDE HÉTÉROARYLCARBOXYLIQUE
  申请人：AJINOMOTO KK

  公开号：WO2013187533A1

  公开（公告）日：2013-12-19

  Compounds represented by the following formula (I); wherein each symbol is as defined in the specification, are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

  以下公式（I）代表的化合物；其中每个符号如规范中定义，对于具有丝氨酸蛋白酶抑制作用的高血糖抑制剂以及糖尿病的预防或治疗药物是有用的。